Adequate liver function must be demonstrated, defined as:Xx_NEWLINE_xXAdequate liver function must be demonstrated, defined as:Xx_NEWLINE_xXDemonstrated adequate organ function within 14 days of Cycle 1 Day 1 (C1D1).Xx_NEWLINE_xXInadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:Xx_NEWLINE_xXInadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:Xx_NEWLINE_xXThe patient has adequate baseline organ function, as demonstrated by the following:Xx_NEWLINE_xXThe patient has adequate baseline hematologic function, as demonstrated by the following:Xx_NEWLINE_xXFor subjects with liver metastasis, adequate liver function is demonstrated by serum bilirubin =< 2 x ULNXx_NEWLINE_xXFor subjects with liver metastasis, adequate liver function is demonstrated by AST/ALT =< 5.0 x ULNXx_NEWLINE_xXAdequate bone marrow reserve as demonstrated by :Xx_NEWLINE_xXAdequate liver function as demonstrated by:Xx_NEWLINE_xXInadequate organ and marrow function as demonstrated by any of the following laboratory values. Transfusions intended to elevate any parameters below solely for the intent of meeting study eligibility are not permitted.Xx_NEWLINE_xXParticipant must have adequate liver function as demonstrated by:Xx_NEWLINE_xXParticipant must have adequate liver function as demonstrated by:Xx_NEWLINE_xXRecent history of inadequate bone marrow reserve as demonstrated by the following:Xx_NEWLINE_xXInadequate liver function at screening as demonstrated by the following:Xx_NEWLINE_xXInadequate organ function or bone marrow reserve as demonstrated by the following laboratory values:Xx_NEWLINE_xXImpaired hepatic or renal function as demonstrated by any of the following laboratory values:Xx_NEWLINE_xXEvidence of adequate cardiac function as demonstrated by EKG and/or echocardiography.Xx_NEWLINE_xXAdequate cardiac function as demonstrated by electrocardiogram (EKG) and/or echocardiographic evidence (may be performed within 30 days prior to treatment)Xx_NEWLINE_xXAdequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at baselineXx_NEWLINE_xXMust have adequate organ function as demonstrated by the following:Xx_NEWLINE_xXAdequate baseline organ function, as demonstrated by the following:Xx_NEWLINE_xXAdequate baseline hematologic function, as demonstrated by the following:Xx_NEWLINE_xXDemonstrated adequate organ function within 14 days of treatment initiation.Xx_NEWLINE_xXSubject must have adequate liver function as demonstrated by:Xx_NEWLINE_xXInadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:Xx_NEWLINE_xXInadequate liver function at screening and Day 1 (before drug administration) as demonstrated by:Xx_NEWLINE_xXAdequate bone marrow reserve, hepatic and renal function, as demonstrated by:Xx_NEWLINE_xXDemonstrated progression on abiraterone and/or enzalutamideXx_NEWLINE_xXAdequate organ function, demonstrated by the following laboratory values:Xx_NEWLINE_xXHas adequate bone marrow reserve, hepatic and renal function, as demonstrated by:Xx_NEWLINE_xXAdequate renal, hepatic, and bone marrow function demonstrated by protocol-specified laboratory parameters at the screening visit.Xx_NEWLINE_xXSubject has adequate bone marrow, renal and hepatic function at baseline, as demonstrated by the following:Xx_NEWLINE_xXAdequate bone marrow reserve as demonstrated byXx_NEWLINE_xXAdequate liver function as demonstrated byXx_NEWLINE_xX